Revenue reached $286.0M in 2026Q3 with 58.1% year-over-year growth and 19.0% operating margin, yet gross margin remains anchored near 53.3% by the Regeneron profit-share structure versus a 60.9% level seen in 2024Q2.
Kiniksa Pharmaceuticals International, plc (KNSA) annual income statement — 10-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 |
|---|
| Sales/Revenue | 945.96M | 677.56M | 423.24M | 270.26M | 220.18M | 38.54M | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | 58.19% | 60.09% | 56.61% | 22.74% | 471.24% | - | - | - | - | - | - |
| Cost of Goods Sold | 432.7M | 307.41M | 60.91M | 56.52M | 22.89M | 9.1M | 3.81M | 3.28M | 286K | 28K | 22K |
| COGS % of Revenue | - | 45.37% | 14.39% | 20.91% | 10.4% | 23.61% | - | - | - | - | - |
| Gross Profit | 513.27M | 370.15M | 362.33M | 213.74M | 197.28M | 29.44M | -3.81M | -3.28M | -286K | -28K | -22K |
| Gross Margin % | 54.26% | 54.63% | 85.61% | 79.09% | 89.6% | 76.39% | - | - | - | - | - |
| Gross Profit Growth % | - | 2.16% | 69.52% | 8.34% | 570.03% | 873.82% | -16.04% | -1046.5% | -921.43% | -27.27% | - |
| Operating Expenses | 382.8M | 292.93M | 407.94M | 238.93M | 187.51M | 186.08M | 153.56M | 166.68M | 108.16M | 65.4M | 24M |
| OpEx % of Revenue | - | 43.23% | 96.39% | 88.41% | 85.16% | 482.77% | - | - | - | - | - |
| Selling, General & Admin | 247.15M | 196.27M | 168.01M | 129.43M | 97.95M | 85.95M | 43.92M | 33.75M | 21.56M | 9.04M | 6.56M |
| SG&A % of Revenue | - | 28.97% | 39.7% | 47.89% | 44.49% | 222.99% | - | - | - | - | - |
| Research & Development | 135.8M | 96.85M | 111.62M | 76.1M | 65.49M | 99.3M | 109.64M | 132.93M | 86.6M | 56.36M | 17.44M |
| R&D % of Revenue | - | 14.29% | 26.37% | 28.16% | 29.74% | 257.62% | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 128.31M | 33.41M | 24.07M | 835K | 0 | 0 | 0 | 0 | 0 |
| Operating Income | 130.47M | 77.22M | -45.62M | -25.2M | 9.77M | -156.64M | -157.36M | -169.96M | -108.16M | -65.4M | -24M |
| Operating Margin % | 13.79% | 11.4% | -10.78% | -9.32% | 4.44% | -406.38% | - | - | - | - | - |
| Operating Income Growth % | - | 269.28% | -81.04% | -357.81% | 106.24% | 0.46% | 7.41% | -57.14% | -65.38% | -172.48% | - |
| EBITDA | 132.36M | 78.78M | -43.92M | -22.86M | 12.18M | -154.28M | -154.96M | -167.9M | -107.87M | -65.37M | -23.98M |
| EBITDA Margin % | 13.99% | 11.63% | -10.38% | -8.46% | 5.53% | -400.27% | - | - | - | - | - |
| EBITDA Growth % | 233.9% | 279.36% | -92.17% | -287.72% | 107.89% | 0.44% | 7.71% | -55.64% | -65.02% | -172.61% | - |
| D&A (Non-Cash Add-back) | 1.9M | 1.55M | 1.7M | 2.34M | 2.4M | 2.35M | 2.4M | 2.07M | 286K | 28K | 22K |
| EBIT | 142.2M | 88.87M | -36.15M | -16.65M | 11.03M | -156.54M | -156.23M | -163.91M | -108.16M | -65.4M | -24M |
| Net Interest Income | 10.08M | 11.65M | 9.46M | 8.54M | 1.25M | 97K | 1.13M | 6.05M | 0 | 0 | 0 |
| Interest Income | 10.08M | 11.65M | 9.46M | 8.54M | 1.25M | 97K | 1.13M | 6.05M | 4.72M | 529K | 65K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 15.69M | 11.65M | 9.46M | 8.54M | 1.25M | 97K | 1.13M | 6.05M | 4.72M | 529K | 65K |
| Pretax Income | 146.15M | 88.87M | -36.15M | -16.65M | 11.03M | -156.54M | -156.23M | -163.91M | -103.44M | -64.87M | -23.94M |
| Pretax Margin % | 15.45% | 13.12% | -8.54% | -6.16% | 5.01% | -406.13% | - | - | - | - | - |
| Income Tax | 36.58M | 29.86M | 7.04M | -30.74M | -172.34M | 1.39M | 5.15M | -2.05M | -214K | 2K | 36K |
| Effective Tax Rate % | 25.03% | 33.6% | -19.48% | 184.58% | -1563.01% | -0.88% | -3.3% | 1.25% | 0.21% | -0% | -0.15% |
| Net Income | 109.57M | 59.01M | -43.19M | 14.08M | 183.36M | -157.92M | -161.38M | -161.87M | -103.23M | -64.87M | -23.97M |
| Net Margin % | 11.58% | 8.71% | -10.21% | 5.21% | 83.28% | -409.72% | - | - | - | - | - |
| Net Income Growth % | 205.05% | 236.61% | -406.68% | -92.32% | 216.11% | 2.14% | 0.3% | -56.81% | -59.12% | -170.61% | - |
| Net Income (Continuing) | 109.57M | 59.01M | -43.19M | 14.08M | 183.36M | -157.92M | -161.38M | -161.87M | -103.23M | -64.87M | -23.97M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 1.29 | 0.75 | -0.60 | 0.20 | 2.60 | -2.30 | -2.61 | -2.99 | -3.49 | -2.00 | -0.74 |
| EPS Growth % | 191.11% | 225% | -400% | -92.31% | 213.04% | 11.88% | 12.71% | 14.33% | -74.5% | -170.27% | - |
| EPS (Basic) | - | 0.80 | -0.60 | 0.20 | 2.64 | -2.30 | -2.61 | -2.99 | -3.49 | -2.00 | -0.74 |
| Diluted Shares Outstanding | 84.92M | 78.98M | 71.42M | 71.92M | 70.42M | 68.58M | 61.84M | 54.05M | 29.55M | 32.47M | 32.47M |
| Basic Shares Outstanding | 78.19M | 74.2M | 71.42M | 70.06M | 69.38M | 68.58M | 61.84M | 54.05M | 29.55M | 32.47M | 32.47M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying KNSA stock.
For fiscal year 2025, Kiniksa Pharmaceuticals International, plc (KNSA) reported total revenue of $677.6M.
Kiniksa Pharmaceuticals International, plc (KNSA) is profitable, generating $59.0M in net income for the fiscal year ending 2025 with a net profit margin of 8.7%.
Kiniksa Pharmaceuticals International, plc (KNSA) reported an operating income of $77.2M, resulting in an operating profit margin of 11.4%. This margin reflects the operational efficiency of the business before interest and taxes.
Kiniksa Pharmaceuticals International, plc (KNSA) generated $370.1M in gross profit for the year, representing a gross profit margin of 54.6%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Single-product concentration and margin ceiling
Metrics are mathematically derived from official filings.
ARCALYST Drives Exceptional Top-Line Acceleration
Kiniksa's quarterly revenue surged from $108.6M in 2024Q2 to $286.0M in 2026Q3, representing approximately 163% cumulative growth over ten quarters, according to reported financial statements, driven primarily by accelerating ARCALYST new patient starts in the recurrent pericarditis market.
Revenue growth has remained remarkably consistent at 44-72% year-over-year across every reported quarter, suggesting durable market penetration rather than a one-time launch spike. The sequential revenue progression from $202.1M (2025Q4) to $286.0M (2026Q3) appears to reflect both new prescriber adoption and potentially extended duration of therapy, which would increase lifetime patient value. Management's decision to raise 2026 guidance to $980-$995M following Q2 results implies they see no near-term plateau, though the reliance on a single approved product for essentially all commercial revenue concentrates trajectory risk around payer reauthorization dynamics and any future competitive entry into the RP indication.
Gross Margin Ceiling Set by Profit-Share Structure
Kiniksa's gross margin has stabilized in the 53-55% range since a 46.0% trough in 2024Q4, reflecting the structural impact of the Regeneron profit-sharing arrangement, as reported in SEC filings, which permanently caps margins well below the 80-90% observed at asset-owning orphan drug peers.
The 46.0% gross margin in 2024Q4 appears anomalous relative to the surrounding quarters and may reflect a one-time gross-to-net adjustment or cost allocation shift, though the specific driver is not discernible from the data alone. The subsequent stabilization around 53-55% suggests the current margin profile is the structural steady state, which has meaningful valuation implications: Kiniksa's gross margin is roughly half that of Ardelyx (89.5%) and Arcus (96.0%), reflecting the economic reality that a significant portion of ARCALYST economics flows to Regeneron. This margin ceiling means incremental revenue growth translates to profit at a lower rate than typical biotech peers, and any future gross-to-net deterioration from shifting payer mix could compress margins further within an already constrained band.
Commercial Scale-Out Delivers Operating Leverage
Over the ten-quarter period, Kiniksa's SG&A grew approximately 54% from $42.4M to $65.4M while revenue expanded 163%, resulting in operating margin improvement from -0.1% to 19.0%, as reported in recent financial statements, suggesting meaningful commercial infrastructure operating leverage.
The operating leverage profile is striking: SG&A as a percentage of revenue has compressed from 39.0% in 2024Q2 to 22.9% in 2026Q3, indicating the existing commercial infrastructure is absorbing higher volumes without proportional cost increases. This suggests the ARCALYST sales force and patient support model were built with substantial forward capacity, and current growth is leveraging an already-deployed infrastructure. However, operating margin has exhibited quarter-to-quarter volatility (ranging from 9.8% to 19.0% in profitable quarters), largely driven by lumpy R&D spend that swung from $18.8M to $40.9M. Investors should note that operating leverage is currently being partially offset by R&D investment, and the sustainability of the 19.0% operating margin in 2026Q3 depends partly on R&D timing rather than purely commercial efficiency.
SBC Ramp and Tax Effects Cloud EPS Quality
Stock-based compensation accelerated to $13.1M in 2026Q3 from $3.9M in 2025Q4, representing roughly 4.6% of revenue, and EPS growth figures have been distorted by base effects from loss-making prior-year periods, according to Kiniksa's quarterly filings, warranting scrutiny of underlying cash earnings quality.
The dramatic swing in reported EPS growth rates (from 2.5% in 2025Q4 to 143.5% in 2026Q3) is largely an artifact of comparing against depressed or negative prior-year bases rather than reflecting fundamental acceleration, and should be interpreted cautiously. The step-up in SBC from $3.9M in 2025Q4 to $13.1M in 2026Q3—a nearly threefold sequential increase—suggests either a large equity grant vesting event or a structural change in compensation policy, which economically dilutes shareholders even if it does not affect non-GAAP metrics. Net margin has also exhibited volatility (from 6.2% in 2025Q1 to 16.6% in 2026Q3), likely reflecting non-operating items and tax rate variability typical of a company transitioning from loss-making to consistently profitable status. The convergence of net income ($47.3M) below operating income ($54.2M) in 2026Q3 appears normal but the magnitude of the gap warrants monitoring for recurring non-operating charges.
Single-Asset Dependency and Structural Margin Cap
Despite impressive 55-58% recent quarterly revenue growth, Kiniksa remains almost entirely dependent on ARCALYST with a gross margin capped near 55% by the Regeneron profit share, and pipeline candidate KPL-404 faces intensifying CD40 pathway competition from large-cap peers, presenting meaningful downside scenarios if either pillar falters.
The most credible bear case centers on three converging risks: first, any erosion in ARCALYST's competitive position—whether from payer-driven substitution to off-label Kineret or future direct competitors—would disproportionately impact a company where product sales represent nearly all revenue. Second, the Regeneron profit share means Kiniksa captures roughly half the economic value of its lead product, structurally limiting cash generation relative to what a fully-owned asset would produce, which constrains the company's ability to self-fund pipeline development at scale. Third, the KPL-404 program, while providing long-term optionality, is entering a CD40/CD154 competitive landscape that has become significantly more crowded, and the R&D spending volatility observed in the data (ranging from $18.8M to $40.9M quarterly) suggests development timelines and cost profiles remain uncertain. The 2026Q3 operating margin of 19.0% represents a peak that may prove difficult to sustain if R&D normalizes upward or if SG&A must re-accelerate to defend market share.
2025Q1 Marks Sustained Profitability Transition
The 2025Q1 quarter represents the critical inflection point when Kiniksa first achieved positive operating income ($13.3M) and net income ($8.5M), transitioning from sustained losses, and the company has generated consistent profitability in every subsequent quarter, as reported in quarterly financial statements.
Prior to 2025Q1, Kiniksa posted operating losses in every reported quarter (2024Q2 through 2024Q4), with the most severe loss of $19.3M in 2024Q4 coinciding with the lowest gross margin (46.0%) and elevated R&D spend ($35.1M). The inflection appears driven by the crossing of a revenue threshold—approximately $137.8M quarterly—at which the fixed commercial infrastructure becomes self-sustaining. What makes this inflection durable rather than transitory is that operating income has expanded in tandem with revenue growth, reaching $54.2M by 2026Q3, rather than oscillating around breakeven. This pattern suggests the company has passed a structural profitability threshold, though the narrow gross margin band means the durability of this inflection remains tightly coupled to continued top-line momentum in the RP market.